J. Lisnock

发表

Molecular basis for p38 protein kinase inhibitor specificity.

E. A. O'neill, J. Lisnock, A. Tebben, 1998, Biochemistry.

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).

B. Hawes, K. O'neill, J. Lisnock, 2005, Proceedings of the National Academy of Sciences of the United States of America.

The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity.

J. Lisnock, P. Lograsso, G. Scapin, 2003, Chemistry & biology.

A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanes.

Michael E. Lassman, Shirly Pinto, J. Lisnock, 2012, Bioorganic & medicinal chemistry letters.

Deficiency in Inducible Nitric Oxide Synthase Results in Reduced Atherosclerosis in Apolipoprotein E-Deficient Mice

D. Rader, E. Puré, Y. Chao, 2000, The Journal of Immunology.

Metabolic syndrome in mice induced by expressing a transcriptional activator in adipose tissue

J. Lisnock, O. Puig, B. Daugherty, 2012, Transgenic Research.

A target for cholesterol absorption inhibitors in the enterocyte brush border membrane.

Y. Chao, J. Lisnock, B. Pikounis, 2000, Biochimica et biophysica acta.

From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9.

Sujata Sharma, J. Lisnock, P. Orth, 2019, Cell chemical biology.

Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.

J. Lisnock, A. Crespo, Gaochao Zhou, 2016, Bioorganic & medicinal chemistry letters.

Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.

J. Lisnock, A. Crespo, Gaochao Zhou, 2013, Bioorganic & medicinal chemistry letters.

Potent DGAT1 Inhibitors in the Benzimidazole Class with a Pyridyl-oxy-cyclohexanecarboxylic Acid Moiety.

Shirly Pinto, J. Lisnock, R. DeVita, 2013, ACS medicinal chemistry letters.

Metabolic syndrome in mice induced by expressing a transcriptional activator in adipose tissue

J. Lisnock, O. Puig, B. Daugherty, 2012, Transgenic Research.

Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety.

Shirly Pinto, J. Lisnock, R. DeVita, 2014, ACS medicinal chemistry letters.

Multiple strategies for the preparation of a sulfur-35 labeled NPC1L1 radioligand.

J. Lisnock, R. DeVita, M. Garcia-Calvo, 2009, Bioorganic & medicinal chemistry letters.

Apolipoprotein E-Deficient Mice Results in Reduced Atherosclerosis in Deficiency in Inducible Nitric Oxide Synthase

D. Rader, E. Puré, Y. Chao, 2000 .

Time-resolved Forster resonance energy transfer assays for the binding of nucleotide and protein substrates to p38alpha protein kinase.

J. Lisnock, P. Lograsso, R. Cummings, 2005, Analytical biochemistry.

Spiroimidazolidinone NPC1L1 inhibitors. 1: Discovery by 3D-similarity-based virtual screening.

Daniel R McMasters, V. Maiorov, J. Lisnock, 2009, Bioorganic & medicinal chemistry letters.

Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.

J. Lisnock, A. Crespo, Gaochao Zhou, 2015, ACS medicinal chemistry letters.

Pyrazoles as non-classical bioisosteres in prolylcarboxypeptidase (PrCP) inhibitors.

Shirly Pinto, J. Lisnock, M. Garcia-Calvo, 2014, Bioorganic & medicinal chemistry letters.

Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors.

Shirly Pinto, J. Lisnock, M. Garcia-Calvo, 2013, Bioorganic & medicinal chemistry letters.

A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluation.

Michael E. Lassman, Shirly Pinto, J. Lisnock, 2012, Bioorganic & medicinal chemistry letters.

Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy.

Daniel R. McMasters, J. Lisnock, R. DeVita, 2010, Bioorganic & medicinal chemistry letters.

Activation of JNK3 alpha 1 requires both MKK4 and MKK7: kinetic characterization of in vitro phosphorylated JNK3 alpha 1.

P. Griffin, J. Lisnock, B. Frantz, 2000, Biochemistry.

Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.

J. Lisnock, A. Crespo, Gaochao Zhou, 2014, Bioorganic & medicinal chemistry letters.